Riverhead Capital Management’s NovoCure NVCR Stock Holding History

Riverhead Capital Management’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-9,053	Closed	-$197K	–	1561
2018 Q1	$197K	Hold	9,053	–	–	0.01%	1073
2017 Q4	$183K	Hold	9,053	–	–	0.01%	1118
2017 Q3	$180K	Hold	9,053	–	–	0.01%	1031
2017 Q2	$157K	Hold	9,053	–	–	0.01%	1023
2017 Q1	$73K	Hold	9,053	–	–	﹤0.01%	1118
2016 Q4	$71K	Hold	9,053	–	–	﹤0.01%	1108
2016 Q3	$77K	Buy	9,053 +4,301	+91%	+$39.2K	0.01%	1012
2016 Q2	$558K	Sell	4,752 -52,760	-92%	-$661K	0.02%	584
2016 Q1	$673K	Buy	+57,512	New	+$825K	0.01%	749

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

TCM

TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

Tamarack Advisers Carlsbad, California $2.12M AUM 58.09% 1-Year Est. Return

Riverhead Capital Management's NVCR Position: Q2 2018 in Review

Riverhead Capital Management sold out of NovoCure (NVCR) in Q2 2018, closing a stake of 9,053 shares — an estimated $197K sold.

Riverhead Capital Management first reported a position in NVCR in Q1 2016 and held it in 9 quarters. The position peaked at $673K in Q1 2016. 161 funds tracked by Wall St. Rank hold NVCR as of Q2 2018.

Riverhead Capital Management reported no remaining NovoCure position as of Q2 2018 after selling out during the quarter.
Riverhead Capital Management sold 9,053 NovoCure shares in Q2 2018, an estimated $197K.
Riverhead Capital Management first reported a position in NovoCure in Q1 2016 and held it in 9 quarters.
Riverhead Capital Management's NovoCure position peaked at $673K in Q1 2016.
161 funds tracked by Wall St. Rank held NovoCure as of Q2 2018.

Based on Riverhead Capital Management's 13F filing for Q2 2018, filed 10 Aug 2018.